Literature DB >> 8912869

Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system.

J Hua1, R J Muschel.   

Abstract

Matrix metalloproteinases (MMPs) have been implicated in tumor progression, but the exact roles that each member of this family may play in contributing to the behavior of malignant tumors are only beginning to be understood. MMP-9 (gelatinase B or the 92-kDa gelatinase/type IV collagenase) expression has been associated with metastasis in a variety of model systems including that of rat sarcomas generated by transformation of rat embryo cells with rasH and myc. To determine the effect that expression of MMP-9 has in this system, we inhibited the expression of MMP-9 using a hammerhead ribozyme. Introduction of an expression vector for a ribozyme directed against the rat MMP-9 mRNA sequence into a metastatic rat embryo cell line transformed by rasH and myc (2.10.10) that constitutively secretes MMP-9 resulted in the absence of detectable MMP-9 mRNA and loss of released 92-kDa gelatinase activity. These cells were no longer metastatic in a lung colonization assay but retained tumorigenicity. Introduction of an expression vector for a control hammerhead ribozyme had no effect. These data document the requirement for MMP-9 expression in metastasis in this system.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8912869

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  36 in total

Review 1.  Matrix metalloproteinase biology applied to vitreoretinal disorders.

Authors:  C S Sethi; T A Bailey; P J Luthert; N H Chong
Journal:  Br J Ophthalmol       Date:  2000-06       Impact factor: 4.638

Review 2.  The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer.

Authors:  G Cox; W P Steward; K J O'Byrne
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

3.  Transcriptional inhibition of matrix metalloproteinase 9 (MMP-9) activity by a c-fos/estrogen receptor fusion protein is mediated by the proximal AP-1 site of the MMP-9 promoter and correlates with reduced tumor cell invasion.

Authors:  D L Crowe; T N Brown
Journal:  Neoplasia       Date:  1999-10       Impact factor: 5.715

Review 4.  Matrix metalloproteinase inhibitors.

Authors:  Nithya Ramnath; Patrick J Creaven
Journal:  Curr Oncol Rep       Date:  2004-03       Impact factor: 5.075

5.  Expression of metalloproteinases endometrial stromal sarcoma: immunohistochemical study using image analysis.

Authors:  P Liokumovich; I Goldberg; B Davidson; W H Gotlieb; T Zahavi; G Ben-Baruch; I Reder; J Kopolovic
Journal:  J Clin Pathol       Date:  1999-03       Impact factor: 3.411

6.  Enhancement of type IV collagenases by highly metastatic variants of HT1080 fibrosarcoma cells established by a transendothelial invasion system in vitro.

Authors:  T Okada; J Li; M Kodaka; H Okuno
Journal:  Clin Exp Metastasis       Date:  1998-04       Impact factor: 5.150

7.  Matrix metalloproteinase-9, a potential biological marker in invasive pituitary adenomas.

Authors:  Jian Gong; Yunge Zhao; Rana Abdel-Fattah; Samson Amos; Aizhen Xiao; M Beatriz S Lopes; Isa M Hussaini; Edward R Laws
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

8.  Multifunctional role of matrix metalloproteinases in multiple myeloma: a study in the 5T2MM mouse model.

Authors:  Els Van Valckenborgh; Peter I Croucher; Hendrik De Raeve; Chris Carron; Evy De Leenheer; Sylvia Blacher; Laetitia Devy; Agnès Noël; Elke De Bruyne; Kewal Asosingh; Ivan Van Riet; Ben Van Camp; Karin Vanderkerken
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

9.  Matrix metalloproteinases and their inhibitors in gastric cancer.

Authors:  G I Murray; M E Duncan; E Arbuckle; W T Melvin; J E Fothergill
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

10.  Focal adhesion kinase functions as an akt downstream target in migration of colorectal cancer cells.

Authors:  Jolana Turecková; Martina Vojtechová; Michaela Krausová; Eva Sloncová; Vladimír Korínek
Journal:  Transl Oncol       Date:  2009-12       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.